← SynDRA
METHYLDOPA
SynDRA canonical compound SYN0000260 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | DDC |
|---|
| Mechanism of action | Adrenergic receptor agonist |
|---|
| Indication | hypertension |
|---|
| Disease area | cardiology |
|---|
All known targets
- ADRA2A
- ADRA2B
- ADRA2C
- DDC
- ALOX15
- DRD2
- EGFR
- FYN
- KDM4E
- TADA2A
Mechanisms of action (all sources)
- Adrenergic receptor agonist
- ADRA2A AGONIST
- Adrenergic receptor alpha-2 agonist
- ADRA2C AGONIST
- ADRA2B AGONIST
- TADA2A AGONIST
- DRD2 AGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCC4
- ESR2
- ADRA1A
- PTGS2
- ABCC2
- NFE2L2
- MLNR
- MMP1
- MMP9
- MPHOSPH8
- MTOR
- NPY1R
- MC4R
- NPY2R
- NR1I2
- NR3C1
- OPRD1
- OPRK1
- OPRM1
- MC5R
- MBNL1
- MC3R
- PDE4D
- MAPT
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LMNA
- LCK
- KDM4A
- KCNH2
- KAT2A
- HTR6
- HTR3A
- HTR2C
- PDE3A
- PGR
- PDE5A
- SMAD3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ALAT2
- NNMT
- UBA2
- SYK
- SIAE
- SAE1
- PSIP1
- PPBT
- PNMT
- PIP4K2A
- NTMT1
- NTM1A
- MPI
- COMT
- MDR1
- KSYK
- ITPK1
- HNMT
- GPX4
- GNMT
- GEMI
- GAMT
- G3P
- DPOLB
- UHRF1
Drug classes
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Antihypertensive Agents
- Cardiovascular Agents
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Sympatholytics
ATC classes
- C02A · ANTIADRENERGIC AGENTS, CENTRALLY ACTING
- ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Cross-references
Synonyms
- ALDOCLOR-150
- ALDOCLOR-250
- ALDOMET
- ALDORIL 15
- ALDORIL 25
- ALDORIL D30
- ALDORIL D50
- METHYLDOPA AND CHLOROTHIAZIDE
- METHYLDOPA AND HYDROCHLOROTHIAZIDE
- methyldopa (levorotatory)
- aldochlor
- aldomine
- alphamethyldopa
- lederdopa
- (-)-alpha-Methyl-3,4-dihydroxyphenylalanine
- Methyldopa (levorotatory)
- Metildopa
- Methyldopa hydrate
- Methyldopa sesquihydrate
- (-)-.alpha.-methyldopa
- .alpha.-methyl-l-dopa
- Alpha-methyldopa
- Anhydrous methyldopa
- L-.alpha.-methyldopa
- Methyldopa anhydrous
- Methyldopa, anhydrous
- BAYER-1440L
- J9.247I
- MK-351
- NSC-169916
- NSC-760080
- Aldomet
- Dopamet
- Dopegyt
- Lederdopa
- Medomet
- Medopren
Reported adverse events
- Parkinsonism
- Sedation
- Headache
- Hypersensitivity
- Toxic epidermal necrolysis
- Arthralgia
- Myocarditis
- Pancreatitis
- Bell's palsy
Look up METHYLDOPA in the interactive SynDRA portal →